Bliss GVS Pharma has approved a leadership transition, appointing Rahul Adakmol as Chief Executive Officer effective July 15, 2026. The Board of Directors also appointed Santosh Parab as an Additional Director in the capacity of Non-Executive Non-Independent Director effective July 03, 2026. These decisions were taken during a meeting held on July 03, 2026, via Video Conferencing.

Key Appointments

The appointment of Mr. Santosh Parab (DIN: 01622988) adds over 35 years of experience in audit, taxation, and corporate finance to the Board. His profile indicates extensive work with financial institutions such as State Bank of India, ICICI Bank, and Kotak Mahindra Bank. He previously worked with Bliss GVS Pharma Limited, bringing prior familiarity with the company's operations.

Mr. Rahul Adakmol steps into the role of Chief Executive Officer with a background in chemical engineering and an MBA from IIM Bangalore. He brings over 22 years of experience, having held senior leadership positions at Bharat Serums and Vaccines, Dr. Reddy's Laboratories, and Reliance Industries. His expertise spans sales, marketing, manufacturing, and global market expansion across more than 70 countries.

Leadership Transition

The changes follow the resignation of Mr. Narsimha Shibroor Kamath from the position of Chief Executive Officer. Mr. Kamath stepped down effective the close of business hours on July 14, 2026. In his resignation letter, he stated that the decision reflects a belief that the time is right for a leadership transition to guide the company through its next phase of growth. He will continue to serve as the Managing Director of the company.

The Board's decisions were based on the recommendations of the Nomination and Remuneration Committee. The meeting concluded at 04:07 p.m. on July 03, 2026. The disclosures were made pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Summary of Appointments

Bliss GVS Pharma Limited has fixed Wednesday, July 08, 2026, as the record date to determine shareholder entitlement for the final dividend for the financial year ended March 31, 2026. The Board of Directors has recommended a dividend of ₹1.00 per equity share, subject to shareholder approval at the 41st Annual General Meeting. If approved, the payment will be made on or before Friday, August 14, 2026.

The Register of Members and Share Transfer Books will remain closed from Thursday, July 09, 2026, to Wednesday, July 15, 2026, for the 41st Annual General Meeting and dividend payment. The company stated that tax will be deducted at source (TDS) on the dividend payment. For resident shareholders, TDS will be deducted at 10% if PAN is registered, or 20% if not. No tax will be deducted if the total dividend does not exceed ₹5,000.

Key AGM and Dividend Dates

The 41st Annual General Meeting is scheduled to be held on Wednesday, July 15, 2026, at 11:00 AM through Video Conferencing or Other Audio-Visual Means. The agenda includes the adoption of financial statements for FY2025-26, the declaration of the final dividend, and the re-appointment of Mr. Narsimha Shibroor Kamath as Managing Director & CEO.

E-Voting and Participation Details

Remote e-voting facilities are available for shareholders. The e-voting period commences at 9:00 AM on Sunday, July 12, 2026, and concludes at 5:00 PM on Tuesday, July 14, 2026. Shareholders eligible to vote as on the cut-off date of Wednesday, July 08, 2026, may cast their votes electronically during this period or via e-voting during the meeting. The facility is available to at least 1,000 members on a first-come, first-served basis, excluding large shareholders and promoters.

Non-resident shareholders and other entities must submit relevant documents, such as Tax Residency Certificates, to avail of lower treaty rates. Shareholders must submit necessary declarations like Form 15G or 15H by Wednesday, July 08, 2026, to avoid higher deduction.